RxDoctor Payments Data

Tasneem Cheema, MD

Internal Medicine · The Villages, FLNPI 1740489707

Payments from drug & device makers

$1,148in general payments, 2019–2025

Across 58 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Welch Allyn$165
  • Johnson & Johnson$127
  • GSK$125
  • Amgen$123
  • Pfizer$94
  • AbbVie$91
  • plus $424 from 11 others

What the payments were for

  • Food & beverage$95483%
  • Education$293%
  • Other$16514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,148 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$408,083
Medicare patients
928
Services billed
13,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$151,593
OzempicSemaglutide41$72,071
JardianceEmpagliflozin41$64,806
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$45,434
XareltoRivaroxaban38$44,910
JanuviaSitagliptin Phosphate27$36,321
MounjaroTirzepatide23$27,536
ProliaDenosumab11$18,996
MyrbetriqMirabegron11$12,932
ShingrixVaricella-Zoster Ge/As01b/Pf58$12,829
Gabapentin454$12,732
Levothyroxine Sodium885$10,897
Dabigatran EtexilateDabigatran Etexilate Mesylate26$9,934
Atorvastatin Calcium802$8,941
Duloxetine Hcl161$8,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$151,593119 claims
Novo NordiskOzempic$39$72,07141 claims
Boehringer IngelheimJardiance$68$64,80641 claims
GSKTrelegy Ellipta, Shingrix$125$58,26491 claims
Johnson & JohnsonXarelto$127$44,91038 claims
AmgenProlia$123$18,99611 claims
Astellas Pharma US IncMyrbetriq$64$12,93211 claims
AbbVieSynthroid$91$8,211133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in The Villages

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →